The prevalence of type 2 diabetes has risen dramatically during recent decades and there is an urgent need to develop new approaches for therapeutic treatment that provide a combination of benefits, with fewer side effects and better patient outcomes. When diabetes is not managed, it can lead to serious complications including cardiovascular disease (CVD), stroke, blindness, kidney disease and premature mortality. CVD is a major cause of death and disability in diabetes, accounting for 52% of fatalities in those with type 2 diabetes.
New treatments are necessary due to the increasing prevalence of diabetes and its complications. In recent years, therapies that target the actions of glucagon-like peptide-1 (GLP-1) which stimulate insulin secretion through activation of beta cell G protein-coupled receptors (GPCRs) have been successful. This has resulted in substantial interest in targeting other islet GPCRs for diabetic therapies [1-3]. GPCRs are a superfamily of transmembrane receptors that transduce extracellular signals into intracellular responses.
GPCRs are the target of approximately 50% of all recently developed pharmaceutical agents. Our research has shown that targeting GPCRs can counteract defective insulin secretion, low beta cell mass, insulin resistance and inflammation which are key characteristics of diabetes and CVD [1-3]. In this project, G protein-signalling cascades will be characterised in islets using western blotting, peptide assays, cAMP imaging by fluorescence confocal microscopy and GPCR gene knockout studies using CRISP-R (Clustered regularly interspaced short palindromic repeats) gene editing.
Precision proteomics and mass spectrometry will enable the characterization of signalling events including at the levels of post-translational modifications. The effects of specific GPCR agonist therapy on the regulation of glucose tolerance, insulin resistance and inflammation will be determined in vivo. This PhD project represents a significant step in the validation of these islet targets for improved diabetes treatment and care.
Project aims are:
Applicants should hold, or expect to obtain, a First or Upper Second Class Honours Degree in a subject relevant to the proposed area of study.
We may also consider applications from those who hold equivalent qualifications, for example, a Lower Second Class Honours Degree plus a Master’s Degree with Distinction.
In exceptional circumstances, the University may consider a portfolio of evidence from applicants who have appropriate professional experience which is equivalent to the learning outcomes of an Honours degree in lieu of academic qualifications.
If the University receives a large number of applicants for the project, the following desirable criteria may be applied to shortlist applicants for interview.
The University offers the following levels of support:
Full award (full-time PhD fees + DfE level of maintenance grant + RTSG for 3 years).
This scholarship will cover full-time PhD tuition fees and provide the recipient with £18,000 (tbc) maintenance grant per annum for three years (subject to satisfactory academic performance).
This scholarship also comes with £900 per annum for three years as a research training support grant (RTSG) allocation to help support the PhD researcher.
Applicants who already hold a doctoral degree or who have been registered on a programme of research leading to the award of a doctoral degree on a full-time basis for more than one year (or part-time equivalent) are NOT eligible to apply for an award.
Applicants who already hold a doctoral degree or who have been registered on a programme of research leading to the award of a doctoral degree on a full-time basis for more than one year (or part-time equivalent) are NOT eligible to apply for an award.
Part award (full-time PhD fees + 50% DfE level of maintenance grant + RTSG for 3 years).
This scholarship will cover full-time PhD tuition fees and provide the recipient with £8,000 maintenance grant per annum for three years (subject to satisfactory academic performance). This scholarship also comes with £900 per annum for three years as a research training support grant (RTSG) allocation to help support the PhD researcher.
Applicants who already hold a doctoral degree or who have been registered on a programme of research leading to the award of a doctoral degree on a full-time basis for more than one year (or part-time equivalent) are NOT eligible to apply for an award.
Fees only award (PhD fees + RTSG for 3 years).
This scholarship will cover full-time PhD tuition fees for three years (subject to satisfactory academic performance). This scholarship also comes with £900 per annum for three years as a research training support grant (RTSG) allocation to help support the PhD researcher.
Applicants who already hold a doctoral degree or who have been registered on a programme of research leading to the award of a doctoral degree on a full-time basis for more than one year (or part-time equivalent) are NOT eligible to apply for an award.
The scholarship will cover tuition fees at the Home rate and a maintenance allowance of £18,000 (tbc) per annum for three years (subject to satisfactory academic performance).
This scholarship also comes with £900 per annum for three years as a research training support grant (RTSG) allocation to help support the PhD researcher.
Due consideration should be given to financing your studies. Further information on cost of living
McCloskey A, Miskelly M, Flatt PR, McKillop AM (2020) European Journal of Pharmaceutical Sciences. 142:1015104.
McCloskey AG, Miskelly MG, Moore CBT, Nesbit MA, Christie KA, Owolabi AI, Flatt PR, McKillop AM. (2020) Peptides 125:170251.
Moran BM, Flatt PR, McKillop AM. (2016) Acta Diabetol. 53(2):177-88 4.Moran BM, McKillop AM, O'Harte FPM. (2016) Curr Opin Pharmacol. 31:57-62.
Submission deadline
Friday 5 February 2021
12:00AM
Interview Date
Weeks commencing 15th and 22nd March 2021
Preferred student start date
Mid-September 2021
Telephone
Contact by phone
Email
Contact by email